继发性急性髓系白血病的移植物抗白血病效应:EBMT 多中心回顾性登记分析
该研究基于 EBMT 登记数据,纳入 2414 例首次或第二次完全缓解的继发性急性髓系白血病患者,分析异基因移植后 GVHD 与移植物抗白血病效应的关系。结果显示慢性 GVHD 与复发率降低相关,但广泛型慢性 GVHD 和 III-IV 级急性 GVHD 增加非复发死亡并降低总生存。
要点
- 局限型慢性 GVHD 与更低复发率和更好总生存相关
- 广泛型慢性 GVHD 与更高非复发死亡和更差总生存相关
- III-IV 级急性 GVHD 显著增加非复发死亡并降低总生存
核心结论
- 继发性急性髓系白血病对移植物抗白血病效应敏感。
研究设计与样本
- EBMT 急性白血病工作组多中心回顾性登记分析,纳入 2414 例首次(n=2194)或第二次(n=220)完全缓解的继发性急性髓系白血病患者。
- 供者来源包括 HLA 全合同胞(MSD,n=1085)、10/10 无关供者(MUD,n=1066)和 9/10 不合无关供者(MMUD,n=263)。
主要发现
- II-IV 级急性 GVHD 的 100 天发生率为 25%,慢性 GVHD 的 2 年发生率为 38%。
- 复发率随随访时间延长稳步下降,且在慢性 GVHD 患者中显著更低(P < 0·001)。
- 局限型慢性 GVHD(HR = 0·66,P < 0·001)和广泛型慢性 GVHD(HR = 0·52,P < 0·001)均与更低的复发发生率相关。
- III-IV 级急性 GVHD(HR = 7·04,P < 0·001)、局限型慢性 GVHD(HR = 1·42,P = 0·03)和广泛型慢性 GVHD(HR = 3·97,P < 0·001)均与更高的非复发死亡相关。
- 局限型慢性 GVHD 患者总生存更好(HR = 0·61,P < 0·001);III-IV 级急性 GVHD(HR = 3·16,P < 0·001)和广泛型慢性 GVHD(HR = 1·21,P = 0·03)与更差总生存相关。
关键数值与推荐
- 与 HLA 全合同胞供者相比,MUD 受者复发风险更低(HR = 0·82,P = 0·03)但非复发死亡更高(HR = 1·38,P = 0·004)。
临床怎么用
- 在继发性急性髓系白血病异基因移植中,局限型慢性 GVHD 与更优生存相关,而 III-IV 级急性 GVHD 和广泛型慢性 GVHD 与更差生存相关。
- MUD 移植虽降低复发风险但增加非复发死亡,临床决策需权衡二者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We assessed the susceptibility of secondary acute myeloid leukaemia (sAML) to graft-versus-leukaemia effects. Data from 2414 sAML patients in first (n = 2194) or second (n = 220) complete remission were included. They were given grafts from human leucocyte antigen (HLA)-matched sibling (MSD, n = 1085), 10/10 unrelated donor (MUD, n = 1066) or 9/10 mismatched unrelated donor (MMUD, n = 263). The 100-day incidence of grade II-IV acute graft-versus-host disease (GVHD) was 25% while 2-year incidence of chronic GVHD was 38%. Relapse rates declined steadily by duration of follow-up and were significantly lower in patients with chronic GVHD (P < 0·001). Limited (hazard ratio [HR] = 0·66, P < 0·001) and extensive (HR = 0·52, P < 0·001) chronic GVHD were associated with a lower incidence of relapse. Each grade III-IV acute (HR = 7·04, P < 0·001) as well as limited (HR = 1·42, P = 0·03) and extensive (HR = 3·97, P < 0·001) chronic GVHD were associated with higher non-relapse mortality (NRM). This translated to better overall survival (OS; HR = 0·61, P < 0·001) in patients with limited chronic GVHD. In contrast, grade III-IV acute and extensive chronic GVHD were associated with worse OS (HR = 3·16, P < 0·001 and HR = 1·21, P = 0·03, respectively). Further, in comparison to HLA-identical sibling recipients, MUD recipients had a lower risk of relapse (HR = 0·82, P = 0·03) but higher NRM (HR = 1·38, P = 0·004). In conclusion, these data demonstrate that sAML is susceptible to graft-versus-leukaemia effects.
引用
- Baron F, Labopin M, Savani BN, et al. Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. Br J Haematol. 2019. PMID: 31612473. doi:10.1111/bjh.16185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。